Navigation Links
New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
Date:9/19/2007

postmenopausal women with osteoporosis, Boniva increases bone mineral density and reduces the incidence of vertebral fractures. Boniva also may be considered for postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and reduce the risk of vertebral fracture.

Once-monthly Boniva is a small, film-coated, easy-to-swallow tablet dosed at 150 mg. Patients should take Boniva with plain water on an empty stomach upon rising in the morning. They should remain upright and avoid food, drink and other medications for at least 60 minutes.

Patients who take Boniva are eligible to sign up for MyBONIVA, a program designed to help enhance compliance (taking therapy as directed) and persistence with this unique once-monthly regimen. For more information on this program call 1-800-4BONIVA or visit http://www.MyBoniva.com.

Important Safety Information

Boniva is contraindicated in patients unable to stand or sit upright for at least 60 minutes, with uncorrected hypocalcemia, or with known hypersensitivity to any component of Boniva. Boniva, like other bisphosphonates administered orally, may cause upper gastrointestinal disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer. Boniva is not recommended in patients with severe renal impairment. Adequate intake of calcium and Vitamin D is important in all patients.

Rarely, patients have reported severe bone, joint and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Additionally, osteonecrosis of the jaw has been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures.

The most commonly reported adverse events with once-monthly Boniva regardless of causality were abdominal pain (Boniva 150 mg 7.8% vs. Boniva 2.5 mg 5.3%), hypertension (6.3% vs. 7.3%), dyspepsia (5.6% vs. 7.1%
'/>"/>

SOURCE Roche and GSK
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
(Date:7/31/2014)... SPRINGFIELD, Ill. , July 31, 2014 /PRNewswire/ ... (LRS) announced a new extension to its PageCenterX ... software is designed to provide downtime ... unplanned system outages. LRS is releasing the product ... the healthcare environment, EMR applications experience outages for ...
(Date:7/31/2014)... July 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... the second quarter 2014, on Thursday, August 7, 2014 ... a live webcast and conference call at 8:00 a.m. ... management will host the call and webcast to discuss ... may be accessed by calling (800) 708-4540 (domestic) or ...
Breaking Medicine Technology:Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2LRS Announces Downtime Reporting Solution for Healthcare 2Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2
... - Planning for Phase 3 Trial Initiation on ... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced ... largest Contract Research,Organisation, to utilise their services for ... includes the execution of the,Phase 3 clinical trial ...
... Presentations on the Topic of Drug Repurposing and ... Indian Clinical ... Inc., an,oncology-focused, clinical-stage biopharmaceutical company, announced today,that Chief Executive Officer, ... present at the 234th American Chemical,Society National Meeting on Sunday, ...
Cached Medicine Technology:Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 2Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:7/31/2014)... Ticket Down is a reputable source for ... Santa Clara, California. Fans in the United States of international soccer ... club and national teams in the world. Coming off the heels ... the best time to be a fan of soccer in the ... on American soil this year, as well as international friendly games ...
(Date:7/31/2014)... 2014 David Kekich, anti-aging icon ... ) is thrilled that the acceptance of his ... Artificial Intelligence (AI) algorithms and then screening thousands ... acceptance. , “It took longer than ... proof is in," said Kekich. "Client acceptance is ...
(Date:7/31/2014)... 2014 Much of the liver,s metabolic function is ... and UC Irvine researchers have now found two ... published online today in Cell , reveals new ... points the way to more focused drug treatments for ... diabetes. , Paolo Sassone-Corsi, UCI,s Donald Bren Professor of ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... business-to-business publication dedicated to delivering cutting-edge information ... biopharmaceuticals and therapeutics, recently launched its newly ... new website optimizes navigation by providing visitors ... manufacturing, analytical and strategic business areas. As ...
(Date:7/31/2014)... teens never outgrow their "growing pains," according to new ... affecting teens, participation in sports and other activities, a ... can become chronic, the researchers cautioned. "We can ... people between the ages of 12 and 19 experience ... Rathleff, a physiotherapist from Aarhus University. "Seven percent of ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 2Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 3Health News:MaxLife Solution™ Expands Distribution Globally for Breakthrough Anti-Inflammatory Support Supplement – InflaGene™ 2Health News:Strict genomic partitioning by biological clock separates key metabolic functions 2Health News:BioProcess International Launches New Website 2Health News:Teen 'Growing Pains' May Persist For Years 2
... , CLEVELAND, Aug. 12 The Sisters of Charity ... its legal department. Jerse will serve as General Counsel to St. ... Counsel for the health system. , , "We ... expertise that Shannon brings to this new position," says Sister Judith ...
... patients, survey found , WEDNESDAY, Aug. 12 (HealthDay News) ... problems, according to the results of a patient survey. ... 78, who had two types of cervical neck operations ... Before the surgery, 86.4 percent of the patients reported ...
... NEW YORK, Aug. 12 Gloria Gibbons, President of Ogilvy ... have been appointed Joint Worldwide CEOs of Ogilvy Healthworld, reporting to ... In making the announcement, Mr. Young said, "Donna and Gloria ... individuals. Their joint mandate is to drive the business as ...
... ... business culture and long history of technology innovation to enhance research, development and innovation ... Scottsdale, AZ ... management and security, today announced the expansion of its global operations with the opening ...
... now the greatest threat to the health of Americans, finding an effective ... a new study in the August 2009 issue of the ... portion and calorie-controlled meal replacements used in a structured weight-loss program are ... The st u dy looked at ...
... , SWARTZ CREEK, Mich., Aug. 12 Diplomat ... 2009 Inc. 500, Inc.,s annual ranking of the fastest-growing ... at 235 in the nation is an amazing achievement, the additional details are ... Hagerman refers to are these: , , , ...
Cached Medicine News:Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 2Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 3Health News:Surgery for Neck Pain May Also Relieve Headaches 2Health News:Joint Worldwide CEO's of Ogilvy Healthworld Named 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 3Health News:New Published Diet Study Reveals Meal Replacements as Top Strategy for Weight Loss 2Health News:Diplomat Specialty Pharmacy Honored By Inc. Magazine As One Of The Nation's Fastest-Growing Companies 2
... V have an exceptionally sensitive plethysmograph for penile and ... Model 1061 shown below, but does not have the ... Penilab V has a Doppler. These are ready-to-use ... get started. Latex rubber cuffs do go bad ...
... When your patients come to ... want answers they can understand. Then ... RigiScan Plus Rigidity Assessment System can ... patients' penile rigidity and tumescence data...and ...
The very bright medical maginifier lamp for examination and labratory....
... were designed with the surgeon in mind. ... and value. It offers comfort and ease ... hands. The broader, anatomical design allows for ... offers sensitivity and an effective grip, wet ...
Medicine Products: